Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.
Hosted on MSN13h
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares RiseThe stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...
A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, ...
During JPM week, virtual care companies strut their plans to make GLP-1 drugs work harder, cost less
Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...
Mounjaro's label notes, however, that the drug is contraindicated in patients with gastroparesis. Novo Nordisk sent pharmaphorum a statement noting that GLP-1 agonists have been used for years to ...
Novo Nordisk gets CHMP backing for oral GLP-1 agonist Rybelsus in its marketing battle with Eli Lilly, plus positive opinions for Bayer’s diabetes drug Nubeqa, Emergent’s cholera vaccine, and more ...
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...
Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback